Killick Capital

Killick Capital Inc. is a private equity firm founded in 2004 and headquartered in St. John's, Newfoundland and Labrador. The firm specializes in acquisitions, restructurings, and investments in undervalued companies, with a particular focus on the aerospace sector and private businesses located in Atlantic Canada. Killick Capital aims to partner with its portfolio companies, often taking board membership to enhance collaboration and drive growth. The firm provides capital for expansion and acquisition financing, positioning itself as a key player in supporting the development of businesses within its targeted regions.

Joe McKenna

Partner and Vice President, Investments

Tom Williams

Vice President, Investments and Partner

Past deals in Newfoundland

Landwash Brewery

Venture Round in 2022
Landwash Brewery is a craft brewery that specializes in producing a diverse range of beers, including blonde ale, New England IPA, and sour ale infused with Newfoundland sea salt. The brewery features a taproom where patrons can enjoy its offerings in a social setting, complemented by a retail store that provides access to its products. Designed to create a welcoming atmosphere for friends and family, Landwash Brewery aims to enhance leisure experiences for its customers while showcasing the unique flavors of its craft beers.

Sequence Bio

Seed Round in 2016
Sequence Bio is a biotechnology company focused on advancing drug discovery and development through genome therapy. Leveraging the unique genetic characteristics of isolated populations, particularly those in Newfoundland, the company collects DNA and health information to enhance the identification of drug targets. This approach aims to improve the treatment of complex and inherited diseases, ultimately addressing the high failure rate of drug candidates and expediting access to effective therapies for patients in need. By utilizing genetic insights, Sequence Bio seeks to transform the landscape of medicine and deliver better health outcomes.

Sequence Bio

Pre Seed Round in 2015
Sequence Bio is a biotechnology company focused on advancing drug discovery and development through genome therapy. Leveraging the unique genetic characteristics of isolated populations, particularly those in Newfoundland, the company collects DNA and health information to enhance the identification of drug targets. This approach aims to improve the treatment of complex and inherited diseases, ultimately addressing the high failure rate of drug candidates and expediting access to effective therapies for patients in need. By utilizing genetic insights, Sequence Bio seeks to transform the landscape of medicine and deliver better health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.